TrialCirculation2019

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

David Fitchett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.